Performance evaluation of antibody-based point-of-care devices intended for the identification of immune responses to SARS-CoV-2.
Performance evaluation of antibody-based point-of-care devices intended for the identification of immune responses to SARS-CoV-2.
复制标题
DOI：
10.1016/j.diagmicrobio.2020.115298
复制
发表时间：
2021-04
影响因子：
2.9
通讯作者：
Lee WT
中科院分区：
文献类型：
--
作者：
Furuya AKM;Wagner C;Connors J;Bodnar J;Miller T;Ryman NL;Warszycki CJ;Wong SJ;Walsh AC;McDonough KA;Lee WT
由严重急性呼吸综合征冠状病毒（SARS-CoV-2）引起的新型冠状病毒疫情于2019年12月在中国武汉首次发现。当地疫情迅速上升到大流行水平，已蔓延到188个国家，全球病例超过1900万例，死亡732，467人。目前推荐的检测方法是对鼻咽拭子或鼻拭子和/或口咽拭子进行基于RT-PCR的检测，以检测SARS-CoV-2感染，从而诊断急性感染。然而，目前迫切需要一种快速准确的基于抗体的即时检测方法，以快速识别可能被主动病例发现和监测工作遗漏的人群中的SARS-CoV-2感染证据。血清学测试测量感染后血清中抗体的存在。在这里，我们比较了6个市售的抗体为基础的床旁设备的性能特点和他们的潜力，在一段时间内感染的SARS-CoV-2的个人识别。
The novel coronavirus outbreak caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2) was first identified in December of 2019 in Wuhan, China. The local outbreak quickly rose to pandemic level that has spread to more than 188 countries with more than 19 million cases and 732,467 deaths worldwide. The current recommendation for testing is RT-PCR based tests of nasopharyngeal or alternatively nasal- and/or oropharyngeal swabs that detects infection with SARS-CoV-2 to diagnose acute infection. However, there is an urgent need for a quick and accurate antibody-based point-of-care test method to quickly identify evidence of SARS-CoV-2 infection among people who might be missed through active case finding and surveillance efforts. Serology tests measure the presence of antibodies in serum after infection. Here we compared the performance characteristics of 6 commercially available antibody-based point-of-care devices and their potential for identification of individuals infected at some time by SARS-CoV-2.
影响因子：
5
作者：
Yang, He S.;Racine-Brzostek, Sabrina E.;Zhao, Zhen
通讯作者：
Zhao, Zhen